$21.740
-2.072 (-9.53%)Zum Schluss
VTVT-News
VTVT-Events
vTv Therapeutics Completes Enrollment in CATT1 Trial
"Completing enrollment in the Phase 3 CATT1 trial is a significant milestone for vTv, and we look forward to reporting topline results in mid 2027," said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics. "In October we also randomized the first participant in Hybrid CATT1, our Phase 2a study of cadisegliatin in people with T1D who use hybrid closed-loop insulin delivery systems. As the experts at our KOL event made clear, hypoglycemia and its broader impact on blood glucose control remain a persistent burden for people with T1D even with the most advanced insulin delivery technology, and cadisegliatin aims to address exactly that."
vTv Therapeutics Randomizes First Participant in T1D Study
vTv Therapeutics announced that the first participant has been randomized in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in individuals with T1D who use hybrid closed-loop, or HCL, insulin delivery systems. The company expects the results to provide insight into cadisegliatin's potential in this growing segment of the T1D population and to inform additional clinical studies.
S&P 500 Ends Three-Day Gain as 10-Year Treasury Yield Hits New High
S&P 500 broke a string of three consecutive gaining sessions, backing away from yesterday's record highs. Investors took greater caution as the yield on the 10-year Treasury note hit a fresh 24-year high of 5.36% before relatively strong demand in today's 10-year auction drove that rate back down to 5.28%, driving some relief into the equity space.Healthcare was the best-performing sector in the S&P 500 on Wednesday while Basic Materials and Industrials were the two worst areas of the market. Precious metals stocks were also weighed down by multi-week lows in Gold and Silver prices. Tech was mixed again, with profit-taking among some of the biggest cybersecurity names that had seen record highs overnight, as Palo Alto Networksfell 3% and CrowdStrikefell 5% . Computer hardware names were generally higher however, paced by 4% gains in Everpure. Also of note, Micronrebounded to post 4% gains after opening the day 3% lower due to labor action in Taiwan.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Applied Digitalup 4.1%Richardson Electronicsup 1.8%ALSO HIGHER -Wolfspeedup 20.8% after announcing a $1.5B 30-year loan from Department of WarvTv Therapeuticsup 5.5% after securing Orphan Drug Designation for HPPDLattice Semiconductorup 2.0% after announcing Arm collaboration on AI data center infrastructureDOWN AFTER EARNINGS -Resources Connectiondown 12.6%Levi Straussdown 1.6%ALSO LOWER -MicroVision.down 7.2% after FY26 outlookONE Gasdown 1.4% after downgrade to Hold at JefferiesCostco Wholesaledown 0.3% after September SSS data
vTv Therapeutics HPPD Receives FDA Orphan Drug Designation
vTv Therapeutics announced that the FDA has granted Orphan Drug Designation to HPPD, the company's oral Nrf2/Bach1 modulator. HPPD is being investigated as a treatment for sickle cell disease. "The FDA's Orphan Drug Designation reinforces both the urgency of the unmet need in this devastating disease and the opportunity to bring forward potential new therapeutic approaches," said Paul Sekhri, chairman, president, and CEO of vTv Therapeutics. "Receiving this designation marks an important inflection point for this program and strengthens vTv's ability to advance strategic partnering discussions for HPPD while continuing to develop cadisegliatin in T1D."
vTv Therapeutics Completes Enrollment of 166 Patients in Cadisegliatin Study
vTv Therapeutics announced on October 5 that the company has completed enrollment of its Phase 3 Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes study. A total of 166 patients have been randomized in the study evaluating cadisegliatin, a potential first-in-class oral, liver-selective glucokinase activator that has received Breakthrough Therapy designation from the FDA as an adjunctive therapy to insulin for the treatment of T1D. "Completing enrollment for the CATT1 study is a significant milestone for vTv, and we're deeply grateful to the study participants whose commitment made this possible. Cadisegliatin has the potential to reduce the risk of hypoglycemia, which remains a significant unmet need for people living with T1D, and we look forward to completing the study and reporting topline results in mid 2027," said Paul Sekhri, chairman, president and CEO of vTv Therapeutics.
Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.